These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 1286573)
1. In vitro activity of amphotericin B, hamycin and their novel water-soluble compounds against pathogenic yeasts. Sekhon AS; Padhye AA; Garg AK; Hamir Z Chemotherapy; 1992; 38(5):297-302. PubMed ID: 1286573 [TBL] [Abstract][Full Text] [Related]
2. Effect of culture media on in vitro susceptibility testing of fluconazole against some yeasts. Sekhon AS; Garg AK; Hamir Z Mycoses; 1991; 34(7-8):319-22. PubMed ID: 1803235 [TBL] [Abstract][Full Text] [Related]
3. Itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts. Lombardi G; Gramegna G; Cavanna C; Poma G; Marangoni E; Michelone G Mycopathologia; 1989 Apr; 106(1):31-4. PubMed ID: 2549421 [TBL] [Abstract][Full Text] [Related]
4. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest. Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981 [TBL] [Abstract][Full Text] [Related]
5. Patterns of amphotericin B killing kinetics against seven Candida species. Cantón E; Pemán J; Gobernado M; Viudes A; Espinel-Ingroff A Antimicrob Agents Chemother; 2004 Jul; 48(7):2477-82. PubMed ID: 15215097 [TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole. Morace G; Manzara S; Dettori G Chemotherapy; 1991; 37(1):23-31. PubMed ID: 2013239 [TBL] [Abstract][Full Text] [Related]
7. [In vitro antifungal activity of itraconazole, a new triazole antifungal agent, against clinical isolates from patients with systemic mycoses]. Uchida K; Matsuzaka A; Aoki K; Yamaguchi H Jpn J Antibiot; 1991 May; 44(5):562-70. PubMed ID: 1652654 [TBL] [Abstract][Full Text] [Related]
8. [In vitro amphotericin B susceptibility of korean bloodstream yeast isolates assessed by the CLSI broth microdilution method, Etest, and Minimum fungicidal concentration test]. Park JY; Shin JH; Uh Y; Kim EC; Kee SJ; Kim SH; Shin MG; Suh SP; Ryang DW Korean J Lab Med; 2008 Oct; 28(5):346-52. PubMed ID: 18971615 [TBL] [Abstract][Full Text] [Related]
9. Role of yeasts as nosocomial pathogens & their susceptibility to fluconazole & amphotericin B. Prasad KN; Agarwal J; Dixit AK; Tiwari DP; Dhole TN; Ayyagari A Indian J Med Res; 1999 Jul; 110():11-7. PubMed ID: 10709333 [TBL] [Abstract][Full Text] [Related]
10. Antifungal Activity of Chitosan-Coated Poly(lactic-co-glycolic) Acid Nanoparticles Containing Amphotericin B. Ludwig DB; de Camargo LEA; Khalil NM; Auler ME; Mainardes RM Mycopathologia; 2018 Aug; 183(4):659-668. PubMed ID: 29497926 [TBL] [Abstract][Full Text] [Related]
11. Combined in vitro activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans and Candida albicans. Chen HH; Liushih RN; Hsieh WC Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1982 May; 15(2):106-12. PubMed ID: 7047097 [TBL] [Abstract][Full Text] [Related]
12. Relationship between in vitro activities of amphotericin B and flucytosine and pH for clinical yeast and mold isolates. te Dorsthorst DT; Verweij PE; Meis JF; Mouton JW Antimicrob Agents Chemother; 2005 Aug; 49(8):3341-6. PubMed ID: 16048945 [TBL] [Abstract][Full Text] [Related]
13. In-vitro activity of cilofungin (LY121019) in comparison with amphotericin B. Meunier F; Lambert C; Van der Auwera P J Antimicrob Chemother; 1989 Sep; 24(3):325-31. PubMed ID: 2681118 [TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Pfaller MA; Messer SA; Bolmström A Diagn Microbiol Infect Dis; 1998 Nov; 32(3):223-7. PubMed ID: 9884840 [TBL] [Abstract][Full Text] [Related]
16. Antifungal drug resistance in pathogenic fungi. Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500 [TBL] [Abstract][Full Text] [Related]
17. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. Espinel-Ingroff A; Kerkering TM; Goldson PR; Shadomy S J Clin Microbiol; 1991 Jun; 29(6):1089-94. PubMed ID: 1864923 [TBL] [Abstract][Full Text] [Related]
18. [Antifungal susceptibility of yeasts by Etest. Comparison of 3 media]. Tapia C; León E; Palavecino E Rev Med Chil; 2003 Mar; 131(3):299-302. PubMed ID: 12790079 [TBL] [Abstract][Full Text] [Related]
19. Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi. Herreros E; Martinez CM; Almela MJ; Marriott MS; De Las Heras FG; Gargallo-Viola D Antimicrob Agents Chemother; 1998 Nov; 42(11):2863-9. PubMed ID: 9797217 [TBL] [Abstract][Full Text] [Related]
20. A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: a multicenter study. Jessup C; Reyes G; Fothergill A; McCarthy D; Rinaldi M; Messer S; Pfaller M; Ghannoum M J Chemother; 2000 Feb; 12(1):22-9. PubMed ID: 10768512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]